Tarsus Pharmaceuticals, Inc. (TARS)

Nasdaq Biotechnology Diagnostics SIC: 2836
A
Pipeline Grade

Financial Position (from SEC Filings)

$104.2M
Cash & Equivalents
$24.7M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$2,584M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
LOTILANER
XDEMVY 		APPROVED Blepharitis, Demodectic Blepharitis, Demodex Blepharitis, Demodex Infestation, Demodex Infestation of Eyelid, Healthy, Healthy Volunteer, Lyme Disease, Meibomian Gland Dysfunction, Ocular Rosacea, Papulopustular Rosacea

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for TARS.

SEC EDGAR Filings

All SEC filings for Tarsus Pharmaceuticals, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.